The causes and treatment of hyperkalemia across the continuum of kidney function and with kidney replacement therapies. The causes and treatment of hyperkalemia.

Slides:

Advertisements

Similar presentations

Journal of the American Society of Hypertension

Advertisements

Intensive Hemodialysis: Applied Clinical Practice

Prior Trials of RAAS Inhibitors

Presenters Biff F. Palmer, MD Robert Toto, MD

Current State of Hyperkalemia Management

Introduction: Alarming Statistics Causes of Death in Prevalent Dialysis Patients,

PCP Perspectives Pathophysiologic Principles in the Management of Hyperkalemia.

Hyperkalemia in the Hospital: Collaboration to Improve Transitions of Care.

New Therapies for Hyperkalemia Across the Continuum of Care

At The Cutting Edge of Developments in the Management of Hyperkalemia

Intensive hemodialysis—keeping the faith

Updates Abound in Hyperkalemia Management

PCP Perspectives Clinical Considerations in Hyperkalemia

Suggested approach to patients with dabigatran-associated bleeding

Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.

Biff F. Palmer, MD, Deborah J. Clegg, PhD Mayo Clinic Proceedings

Bushinsky et al. Am J Nephrol 2016;44: (DOI: / )

End-stage renal disease in developing countries

At The Cutting Edge of Developments in the Management of Hyperkalemia

Deborah J. Clegg, PhD, Michael Cody, MD, Biff F. Palmer, MD

Amir Said Alizadeh Naderi, MD, Biff F. Palmer, MD

Multidisciplinary Management of Hyperkalemia:

Intensive hemodialysis—keeping the faith

Section 5: Dialysis Interventions for Treatment of AKI

Volume 88, Issue 2, Pages (August 2015)

Volume 80, Issue 9, Pages (November 2011)

Volume 70, Pages S21-S25 (December 2006)

Volume 90, Issue 3, Pages (September 2016)

HARMONIZE Trial design: Patients with hyperkalemia (K ≥5.1 mEq/L) were randomized in a 1:1:1:1.7 fashion to receive sodium zirconium cyclosilicate (ZS)

Maximizing Organ Protection in Patients With CKD and Comorbidities on RAAS Therapy.

Biff F. Palmer, MD American Journal of Kidney Diseases

Assessing the Burden of Hyperkalemia

Volume 75, Issue 11, Pages (June 2009)

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

Assessing the Burden of Hyperkalemia

Hemodialysis patients represent a tiny subset of all patients with heart disease. Hemodialysis patients represent a tiny subset of all patients with heart.

Carmine Zoccali, Francesca Mallamaci Kidney International

The Iranian model of living renal transplantation

Kaplan–Meier curve for technique survival censored for death, transplantation, and program exit for patient choice for all individuals commencing home.

Volume 65, Issue 4, Pages (April 2004)

Renal replacement therapy in Latin America

Douglas E. Schaubel, Howard I. Morrison, Stanley S.A. Fenton

Ionized-to-total magnesium (Mg) and calcium (Ca) ratios are lower in patients on hemodialysis than those in patients not on dialysis. Ionized-to-total.

Dialyzer clearance of ampicillin/sulbactam in plasma of critically ill patients with AKI undergoing extended dialysis. Dialyzer clearance of ampicillin/sulbactam.

Antioxidant therapy in hemodialysis patients: a systematic review

(A) Distribution of CsA nephrotoxicity lesions according to antihypertensive treatment and CsA C2 levels. (A) Distribution of CsA nephrotoxicity lesions.

Volume 74, Issue 11, Pages (December 2008)

PTH response to the predialysis serum calcium concentration in hemodialysis patients with severe (A), moderate (B), and mild (C) hyperparathyroidism. PTH.

Potential roles of biomarkers

Measured urea permeabilities in the different nephron sections of a rat kidney. Measured urea permeabilities in the different nephron sections of a rat.

Algorithm for management of drug-induced acute interstitial nephritis

The figure shows lack of strong evidence for vitamin D therapy to prevent cardiovascular disease in CKD. Although epidemiologic studies suggest a relationship.

Schematic demonstrating normal and inadequate compensatory mechanisms to maintain BP in response to hemodialysis with ultrafiltration (blue background.

By estimating per-month expenditures for patients aged 45 to 64 as 85% of those documented in a 67-yr-old, it is possible to approximate the financial.

Comparison of Medicare reimbursement to a nephrology practice on an annual per-patient basis for care of a patient on dialysis (at two different frequencies.

Sites of sodium reabsorption and diuretic action along the nephron.

RAASi Enabling in the Modern Era

Pharmacokinetics and pharmacodynamics of diuretic action.

Dialysis limitations. Dialysis limitations. (A) Recent data from observational studies and randomized, clinical trials indicate significant limitations.

A total of 150 dialysis patients washed out of previous antihypertensive therapy (Pretreatment) and underwent periodic evaluation of aortic PWV (line indicating.

The aldosterone paradox refers to the ability of the kidney to stimulate NaCl retention with minimal K+ secretion under conditions of volume depletion.

Model of regulatory pathways for the mineralocorticoid receptor (MR) in intercalated cells: hyperkalemia and volume depletion. Model of regulatory pathways.

Change in coronary artery calcification in patients who were treated with calcium or sevelamer. Change in coronary artery calcification in patients who.

Case-Based Look at Hyperkalemia Identification, Diagnosis, and Management.

Temporal distribution (from time 0 to 720 min after drug administration) of mean dosage-adjusted mycophenolic acid (MPA) concentrations at month 6 after.

Potassium Situations Resolved

Prevalence of primary aldosteronism in patients according to Sixth Joint National Committee (JNC VI) stages of severity of hypertension (stage 1, 140 to.

Pancreas transplantation is performed at transplant centers within 56 of the 58 federally designated donor service areas (DSAs). Pancreas transplantation.

Effect of aspirin (ASA) on serum cytokine concentration in hemodialysis (HD) patients. Effect of aspirin (ASA) on serum cytokine concentration in hemodialysis.

Under normal circumstances, delivery of Na+ to the distal nephron is inversely associated with serum aldosterone levels. Under normal circumstances, delivery.

Presentation transcript:

The causes and treatment of hyperkalemia across the continuum of kidney function and with kidney replacement therapies. The causes and treatment of hyperkalemia across the continuum of kidney function and with kidney replacement therapies. The treatments listed for AKI are indicated for other settings within the continuum when there is severe hyperkalemia or evidence of cardiac toxicity. *K+ binders include sodium polystyrene sulfonate, patiromer, and sodium zirconium cyclosilicate (the latter of which is not yet approved for clinical use). Patiromer and sodium zirconium cyclosilicate have been shown effective in maintaining normokalemia, despite ongoing use of renin-angiotensin-aldosterone (RAAS) blockers. There are no published data on the use of these drugs in patients with kidney transplants. D/C, discontinue; DCT, distal convoluted tubule; HD, hemodialysis. Biff F. Palmer, and Deborah J. Clegg CJASN 2018;13:155-157 ©2018 by American Society of Nephrology